Source: Eur Respir J 2010; 35: 681-687
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J.. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010; 35: 681-687

Member's Comments

No comment yet.

Related content which might interest you: Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome Source: Eur Respir J 2011; 37: 1411-1417 Year: 2011 Lymphoid interstitial pneumonia: clinical features, associations and prognosis Source: Eur Respir J 2006; 28: 364-369 Year: 2006 Pulmonary infiltrates in patients with malignancies: why and how neutropenia influences clinical reasoning Source: Eur Respir J 2009; 33: 6-8 Year: 2009 Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012 Granulomatous lung disease in lymphoma patient after rituximab treatment Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Pulmonary non-Hodgkin‘s lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 Bronchiectasis and autoimmune disease Source: Eur Respir Mon 2011; 52: 192-210 Year: 2011 Interstitial lung disease and fever as main manifestations of angiotropic lymphoma Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Severe lung involvement in systemic scleromyxoedema: a highly unusual finding Source: Eur Respir J 2002; 19: 976-979 Year: 2002 Comparison of registries of interstitial lung diseases in three European countries Source: Eur Respir J 2001; 18: 114S-118S Year: 2001 Desquamative interstitial pneumonia: an analytic review with an emphasis on aetiology Source: Eur Respir Rev 2013; 22: 117-123 Year: 2013 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Drug-induced lung disease in rheumatoid arthritis: critical review of patterns Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective Year: 2009 Endobronchial primary pulmonary non-Hodgkin lymphoma development in a patient with rheumatoid arthritis Source: Eur Respir J 2001; 18: Suppl. 33, 398s Year: 2001 B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Incidence, prevalence and mortality of rheumatoid arthritis-associated interstitial lung disease : a retrospective study Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Impact of BAL lymphocytosis > 15% on the prognosis of chronic idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis: a retrospective nationwide study based on multidisciplinary discussion Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia Source: Eur Respir J 2013; 41: 402-409 Year: 2013